QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).

Trial Details

NCT ID
NCT06749899
Phase
PHASE3
Sponsor
Sun Yat-Sen University Cancer Center
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • QL1706
  • Gemcitabine
  • Cisplatin
  • Intensity-modulated radiotherapy
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Dongguan, Guangdong, China|23.01797,113.74866
  • Foshan, Guangdong, China|23.02677,113.13148
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Age ≥18 and ≤65 years
  • Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma according to WHO criteria.
  • Tumor staged as T4N1 and T1-4N2-3 (AJCC 9th)
  • Stage II: T1-3N2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →